BioMarin Pharma (BMRN) Tops Q2 EPS by 25c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.63 -2.86%
EPS Growth %: +1,016.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.20, $0.25 better than the analyst estimate of $0.95. Revenue for the quarter came in at $990 million versus the consensus estimate of $939.37 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts Lululemon (LULU) at Underperform
- Argo Graphene raises private placement target to $1.5M
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
